Vivek K. Narayan, MD, MS, spotlights 3 case studies of patients with metastatic prostate cancer, delving into the influence of their unique mutational status on treatment decisions, scenarios in which to utilize PARP inhibitor monotherapy vs combination regimens, and key trials that support the use of each approach.
Penn Medicine, Philadelphia: First Mutation-Targeted Bladder Cancer Drug May Be Under-Used | India Education | Latest Education News | Global Educational News indiaeducationdiary.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiaeducationdiary.in Daily Mail and Mail on Sunday newspapers.
While low FGFR biomarker testing rates may be contributing to the drug's slow adoption, the analysis found low uptake even among patients who did get tested.
The first bladder cancer drug targeting a cancer-driving gene mutation has been used relatively little despite its clear efficacy in a clinical trial, suggests a study from researchers at the Perelman School of Medicine at the University of Pennsylvania.